ArticleDigestive diseases and sciences2003
Human colon carcinomas constitutively express and shed type II IL-1 receptor, an IL-1 antagonist.
Article in Digestive diseases and sciences, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Short hairpin RNA (shRNA) of type 2 interleukin-1 receptor (IL1R2) inhibits the proliferation of human osteosarcoma U-2 OS cells.Medical oncology (Northwood, London, England) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We reported earlier that rat intestinal epithelial cells respond to helminth infection, to NSAID injury, and to detachment in vitro with expression of the IL-1RII. Now we have sought to determine whether human colon carcinoma cell lines express, or may be induced to express, this potent IL-1 antagonist. Using RT-PCR, the T84 and HT-29 cell lines constitutively expressed mRNA for the membrane-bound, but not the secreted variant of the receptor. The protein was detectable by immunohistochemistry and was estimated to be 70 kDa by western blotting. TNF treatment of T84 cells led to slightly increased levels of IL-1RII mRNA and to significant increases in soluble protein detected in culture supernatants. Treating T84 cells with inhibitory anti-IL-1RII antibodies led to heightened responsiveness to IL-1, measured as IL-8 production. Expression of the IL-1RII by human epithelial cells has implications in terms of the IL-1 agonist versus antagonist balance in the diseased intestines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.